Grail Files For $100M IPO, Plans To Launch Multi-Cancer Early Detection Test In 2021
Grail hopes to launch its Galleri test in 2021 as a laboratory developed test and submit a PMA to the US FDA in 2023.
You may also be interested in...
Liquid biopsy company Grail raised $390m in a fourth round of financing, bringing the total funding to $1.9bn.
Illumina announced today it will buy back Grail to allow faster adoption of its liquid biopsy test.
Amwell’s increased the size of its IPO and raised $742m when it sold 41.2 million shares at $18 each.